Xbrane enlists CR on Chinese ranibizumab
Sweden’s Xbrane Biopharma plans to bring its biosimilar ranibizumab, Xlucane, to the Chinese market through a partnership with local firm CR Pharma, the companies have revealed following the signing of a “non-binding letter of intent”. Announcing the partnership, CR Pharma said it would be responsible for registering and marketing the biosimilar in China, as well as conducting any necessary clinical research.
You may also be interested in...
Xbrane Biopharma has paused the process of divesting its Primm Pharma subsidiary, developer of the Spherotide long-acting triptorelin formulation, after failing to reach a final agreement with the expected acquirer, Italy’s NewFaDem.
Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.
Xbrane, which has just kicked off a Phase III study for its Xlucane ranibizumab biosimilar to Lucentis, has set a target of ranibizumab generating annual sales of €350m within three years of launch, based on capturing a quarter of the Lucentis market by volume in both Europe and the US.